uploads///blood _

What Analysts Recommend for Edwards Lifesciences

By

Feb. 28 2018, Updated 2:58 p.m. ET

Company overview

Edwards Lifesciences (EW) is a global leader in medical innovation for structural heart disease and critical care monitoring. Its heart valve systems and products are used to replace or repair a patient’s diseased or defective heart valve. Edwards Lifesciences’ product pipeline is focused on the repair or replacement of the mitral and tricuspid valves of the heart.

Cardiovascular disease is the number one cause of death worldwide and ranks at the top in terms of health care spending in almost every country.

Article continues below advertisement

Analyst recommendations

Of the 22 analysts covering Edwards Lifesciences in February 2018, 17 analysts have given the stock a “buy” or a higher rating, while four analysts have given it a “hold” rating. The mean rating for the stock is two with a target price of $144.2.

Peer ratings

Of the ten analysts covering Abiomed (ABMD) in February 2018, eight analysts have given the stock a “buy” or higher rating, while two analysts have given it a “hold” rating. The target price for the stock is $281.2.

Of the eight analysts covering Merit Medical Systems (MMSI) in February 2018, four analysts have given the stock a “strong buy” rating, and three analysts have given it a “buy” rating, while only one analyst has given the stock a “sell” rating. The mean rating for the stock is 1.6 with a target price of $49.86.

Of the 12 analysts covering Teleflex (TFX) in February 2018, ten analysts have given the stock a “buy” or higher rating, while two analysts have given it a “hold” rating. The mean rating for the stock is 1.8 with a target price of $288.3.

In the next part of the series, we’ll take a look at the product portfolio of Edwards Lifesciences.

Advertisement

More From Market Realist